Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study

Zhiguang Li1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and;4 Department of Neurology, Xingtai Third Hospital, Xingtai, P.R. China

Mei Tian1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Hongning Jia1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Xin Li1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Qi Liu1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Xiaomeng Zhou1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Rui Li1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, and

Hui Dong1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, andCorrespondence[email protected]

Yaling Liu1 Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China;2 The Key Laboratory of Neurology (Hebei Medical University), Ministry of Education, Shijiazhuang, Hebei, P.R. China;3 Neurological Laboratory of Hebei Province, Shijiazhuang, Hebei, P.R. China, andCorrespondence[email protected]

show all

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date